Skip to content
BiologicalX

Comparison

Ipamorelin vs Magnesium L-Threonate

Side-by-side of Ipamorelin and Magnesium L-Threonate. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Ipamorelin

  • Pentapeptide GHS-R1a agonist with the cleanest selectivity profile in the GHRP class
  • Minimal cortisol and prolactin elevation at standard doses (substantially less than GHRP-2 or hexarelin)
  • ~2 hour plasma half-life, longest of the synthetic GHRPs
  • Largest human safety database (~600 participants in Helsinn's postoperative ileus phase 2)
  • Standard pairing for CJC-1295 no-DAC at 200 to 300 mcg subcutaneously 2 to 3 times daily
  • Banned by WADA under S2; never reached registration despite phase 2b development

Magnesium L-Threonate

  • Distinct magnesium salt designed for blood-brain barrier penetration; not a higher-quality systemic magnesium
  • Liu 2010 rodent study: elevated CSF magnesium ~15% and increased hippocampal synaptic density
  • Trial portfolio in humans is small and mostly Magtein-funded; cognitive effects are modest where reported
  • Typical dose 1500 to 2000 mg/day delivers only ~108 to 144 mg of elemental magnesium
  • GI tolerability comparable to other magnesium forms; loose stools in a minority at 2000 mg/day
  • Distinct from magnesium glycinate, which is the conventional sleep/anxiety/repletion form

Side-by-side

Attribute Ipamorelin Magnesium L-Threonate
Category peptide supplement
Also known as NNC 26-0161, Aib-His-D-2-Nal-D-Phe-Lys-NH2 Mg-T, MgT, Magtein, magnesium threonate
Half-life (hr) 2 4
Typical dose (mg) 0.2 2000
Dosing frequency 2-3x daily 1 to 3 times daily
Routes subcutaneous, intravenous oral
Onset (hr) 0.25 1
Peak (hr) 1 2
Molecular weight 711.86 294.5
Molecular formula C38H49N9O5 C8H14MgO10
Mechanism Selective GHS-R1a agonist that stimulates pulsatile GH release with minimal cortisol or prolactin co-activation. Suppresses hypothalamic somatostatin and stimulates pituitary somatotrophs. Proposed to deliver magnesium across the blood-brain barrier more effectively than other oral salts via threonate-related transporters, raising CNS magnesium and modulating NMDA receptor function and synaptic plasticity.
Legal status Not FDA approved; advanced through phase 2b in postoperative ileus before discontinuation; research-use-only grey market; banned by WADA OTC dietary supplement
WADA status banned allowed
DEA / Rx Not scheduled (research chemical) OTC supplement (not scheduled)
Pregnancy Insufficient data; not recommended Standard magnesium safety; Mg-T-specific data limited
CAS 170851-70-4 778571-57-6
PubChem CID 11338566 10691810
Wikidata Q1666741 Q27151568

Safety profile

Ipamorelin

Common side effects

  • injection-site irritation
  • vivid dreams
  • transient mild head pressure
  • occasional headache

Contraindications

  • pregnancy
  • active malignancy
  • history of pituitary tumor
  • uncontrolled diabetes

Interactions

  • CJC-1295: synergistic GH release via parallel GHRH and ghrelin pathways; standard pairing(minor)
  • sermorelin: additive GH release; functionally similar pairing to CJC-1295 with shorter GHRH half-life(minor)
  • insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
  • corticosteroids: blunt GH response; reduce expected efficacy(moderate)

Magnesium L-Threonate

Common side effects

  • loose stools
  • mild GI upset
  • headache (rare)
  • fatigue (rare)

Contraindications

  • severe renal impairment (eGFR below 30)
  • hypermagnesemia
  • myasthenia gravis (high doses)
  • concurrent IV magnesium therapy

Interactions

  • tetracyclines and fluoroquinolones: magnesium chelation reduces antibiotic absorption; separate by 2 to 4 hours(moderate)
  • bisphosphonates: reduced absorption; separate by 2 hours minimum(moderate)
  • muscle relaxants and aminoglycosides: potentiated neuromuscular blockade at high doses(moderate)
  • antihypertensives: additive blood pressure reduction at high doses(minor)

Which Should You Take?

Magnesium L-Threonate comes out ahead for most readers on the criteria we weight: 2 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Ipamorelin is the right call when one of the conditionals below applies.

Edge case: If you want to avoid research-only / gray-market sourcing, Magnesium L-Threonate is the more accessible choice.

Default choice: Magnesium L-Threonate. Lower friction to source, and broader goal coverage. Reach for Ipamorelin only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Ipamorelin and Magnesium L-Threonate?

Ipamorelin and Magnesium L-Threonate differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Ipamorelin or Magnesium L-Threonate?

Ipamorelin half-life is 2 hours; Magnesium L-Threonate half-life is 4 hours.

Can you stack Ipamorelin with Magnesium L-Threonate?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper